Physician profile
Paul E Raczynski
NPI 1750316477
$384.21
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2022: $21.33.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.66 | 2019 | |
| Sanofi-Aventis U.S. LLC | $34.55 | 2019 | |
| Amgen INC. | $33.27 | 2019 | |
| Merck Sharp & Dohme LLC | $31.45 | 2019 | |
| Glaxosmithkline, LLC. | $27.93 | 2019 | |
| Pfizer INC. | $26.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.76 | 2019 | |
| Abbvie INC. | $21.33 | 2022 | |
| Sanofi Pasteur INC. | $20.50 | 2019 | |
| Lilly USA, LLC | $14.25 | 2019 | |
| Astellas Pharma US INC | $13.65 | 2019 | |
| Novo Nordisk INC | $11.23 | 2019 | |
| Allergan, INC. | $10.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Raczynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.